Other shoe drops for Newlink after Genentech passes on GDC-0919

Shares of Newlink Genetics Corp. were dented 12.4 percent on Monday after the company reported a failed phase II experiment with lead program indoximod, in combination with taxane chemotherapy, for patients with metastatic breast cancer, based on top-line data.